Literature DB >> 8246563

Cold ischemia and reperfusion each produce pulmonary vasomotor dysfunction in the transplanted lung.

D A Fullerton1, M B Mitchell, R C McIntyre, A Banerjee, D N Campbell, A H Harken, F L Grover.   

Abstract

Pulmonary vascular resistance is significantly increased in the transplanted lung. We hypothesized that the ischemic or reperfusion injuries incurred by the transplanted lung may produce pulmonary vasomotor dysfunction, which in turn may produce increased pulmonary vascular resistance. In a dog model of autologous lung transplantation, the purpose of this study was to examine the following mechanisms of pulmonary vasomotor control and to relate each of them to cold ischemia and to reperfusion: (1) endothelium-dependent cyclic guanosine monophosphate-mediated vasorelaxation (response to acetylcholine 10(-6) mol/L), (2) endothelium-independent cyclic guanosine monophosphate-mediated vasorelaxation (response to sodium nitroprusside 10(-6) mol/L), and beta-adrenergic cyclic adenosine monophosphate-mediated vasorelaxation (response to isoproterenol 10(-6) mol/L). Autologous right lung transplantation was performed in five dogs. At each of three times, two third-order pulmonary arteries were dissected from each transplanted lung and studied: control (immediately after harvest), cold ischemia (3 hours in 4 degrees C saline solution), and cold ischemia plus reperfusion (1 hour after lung reimplantation). The vasorelaxing effects of acetylcholine, sodium nitroprusside, and isoproterenol were studied in isolated pulmonary arterial rings, suspended on fine wire tensiometers in individual organ chambers. Statistical analysis was by analysis of variance. Results demonstrated significant dysfunction of beta-adrenergic cyclic adenosine monophosphate-mediated relaxation after cold ischemia alone, and this dysfunction was exacerbated by reperfusion. Endothelium-dependent cyclic guanosine monophosphate-mediated relaxation was not impaired by cold ischemia alone but was significantly impaired by reperfusion. Endothelium-independent cyclic guanosine monophosphate-mediated relaxation was not impaired by cold ischemia or reperfusion. We conclude that cold ischemia and reperfusion each produce different patterns of pulmonary vasomotor dysfunction. Cumulatively, such dysfunction may contribute to increased pulmonary vascular resistance in the transplanted lung.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8246563

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Inducible nitric oxide synthase inhibition reverses pulmonary arterial dysfunction in lung transplantation.

Authors:  Jing-Xiang Wu; Hong-Wei Zhu; Xu Chen; Jiong-Lin Wei; Xiao-Feng Zhang; Mei-Ying Xu
Journal:  Inflamm Res       Date:  2014-04-24       Impact factor: 4.575

2.  Preventive influence of inhaled nitric oxide on lung ischemia-reperfusion injury.

Authors:  H Yamagishi; C Yamashita; M Okada
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 3.  Ex-vivo lung perfusion therapies: do they add value to organ donation?

Authors:  Amit Lyengar; Alexis Schiazza; Edward Cantu
Journal:  Curr Opin Organ Transplant       Date:  2022-06-01       Impact factor: 2.269

Review 4.  Ischemia-Reperfusion Injury in Lung Transplantation.

Authors:  Toyofumi Fengshi Chen-Yoshikawa
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

5.  Role of nitric oxide and cGMP in the modulation of vascular contraction induced by angiotensin II and Bay K8644 during ischemia/reperfusion.

Authors:  Katarzyna Szadujkis-Szadurska; Grzegorz Grzesk; Leszek Szadujkis-Szadurski; Marta Gajdus; Grzegorz Matusiak
Journal:  Exp Ther Med       Date:  2012-11-30       Impact factor: 2.447

Review 6.  Review 2: Primary graft dysfunction after lung transplant-pathophysiology, clinical considerations and therapeutic targets.

Authors:  Zhaosheng Jin; Ka Chun Suen; Zhiping Wang; Daqing Ma
Journal:  J Anesth       Date:  2020-07-20       Impact factor: 2.078

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.